Different clinical trials for BC patients combining CDK4/6i and checkpoint inhibitors (i.e., PD-1, PD-L1) have been started but the initial results from these ongoing clinical trials do not show enhanced responses for this treatment compared to CDK4/6i monotherapy [71]. Here, CDK4 is linked to breast cancer.